Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

pulation.

Other Preclinical Programs:

-- Preclinical data presented at the 5th Annual International

Anti-Angiogenesis Conference confirmed that Peregrine's fully human,

selective anti-VEGF antibody R84 was as effective as Avastin(R) in

inhibiting tumor growth in a model of human breast cancer. Selective

anti-VEGF agents may have potential advantages over non-selective

approaches.

Avid Bioservices:

-- Wholly owned manufacturing subsidiary Avid Bioservices signed an

agreement with ARIUS Research to produce clinical supplies of their

lead cancer stem cell anti-CD44 antibody.

-- Avid continued to demonstrate strong revenue performance during the

third quarter of fiscal year 2008.

Conference Call

The company will host a conference call today, March 11, 2008 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its third quarter FY 2008 financial results.

To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for approximately 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 18, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infec
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... -- Researchers have discovered a new explanation for differences in ... copies of a certain gene, the more serious the handicap. ... is suspected that it is the amount of copies of ... published in the American Journal of Human Genetics , ... Guy Froyen connected to VIB, a life sciences research institute ...
(Date:12/11/2009)... CAMBRIDGE, Mass., Dec. 11 Gwathmey, ... company specializing in cancer, staph aureus, and cardiovascular ... Pre-clinical Services announced today that Rosalie Dunn, Ph.D., ... Dr. Dunn has over 28 years of experience ... Prior to joining Gwathmey, Dr. Dunn managed ...
(Date:12/10/2009)... Endologix, Inc. (Nasdaq: ELGX ), developer of ... that Dan Lemaitre, former President and CEO of ... effective December 11, 2009. Endologix now has ... Franklin D. Brown, Chairman of the Board, said, ... the Endologix Board of Directors. He has ...
(Date:12/10/2009)... provider of advanced flow measurement, control, and level ... company as Global Level Product Manager effective November ... to enhance market penetration of the level measurement ... Instrument from Lafarge Corp, a manufacturer of building ... and Sales. Bayda will report to Brooks Instrument ...
Breaking Biology Technology:Amount of gene surplus determines severity of mental retardation in males 2Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2Endologix Appoints Dan Lemaitre to its Board of Directors 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3
... the global specialty biopharmaceutical company,announces results for the three months to March 31, 2009. , Financial Highlights, ... ... ... Product sales (excluding ADDERALL XR) $460 million ...
... by Microfluidics and Imaging -- Net Loss Narrowed by $0.07 ... Inc. (Nasdaq: CALP ) today reported its first ... $28.5 million compared to $29.3 million in the first quarter ... of 2008 included $2.9 million of revenue related to product ...
... and VANCOUVER, April 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: ... first quarter financial results will be released on Thursday ... a conference call and live webcast at 4:30 p.m. ... quarter results and provide an update on the business ...
Other Biology Technology:Shire begins the year with a strong performance 2Shire begins the year with a strong performance 3Shire begins the year with a strong performance 4Shire begins the year with a strong performance 5Shire begins the year with a strong performance 6Shire begins the year with a strong performance 7Shire begins the year with a strong performance 8Shire begins the year with a strong performance 9Shire begins the year with a strong performance 10Shire begins the year with a strong performance 11Shire begins the year with a strong performance 12Shire begins the year with a strong performance 13Shire begins the year with a strong performance 14Shire begins the year with a strong performance 15Shire begins the year with a strong performance 16Shire begins the year with a strong performance 17Shire begins the year with a strong performance 18Shire begins the year with a strong performance 19Shire begins the year with a strong performance 20Shire begins the year with a strong performance 21Shire begins the year with a strong performance 22Shire begins the year with a strong performance 23Shire begins the year with a strong performance 24Shire begins the year with a strong performance 25Shire begins the year with a strong performance 26Shire begins the year with a strong performance 27Shire begins the year with a strong performance 28Shire begins the year with a strong performance 29Shire begins the year with a strong performance 30Shire begins the year with a strong performance 31Shire begins the year with a strong performance 32Shire begins the year with a strong performance 33Caliper Life Sciences Reports First Quarter 2009 Results 2Caliper Life Sciences Reports First Quarter 2009 Results 3Caliper Life Sciences Reports First Quarter 2009 Results 4
(Date:12/11/2009)... How does a cell manage to identify and degrade ... the body against serious diseases? The researchers Sabine C. ... Ernst Jarosch of the Max Delbrck Center for Molecular ... piece in this puzzle. In an enzyme complex that ... proteins, they discovered a scaffold regulating the identification and ...
(Date:12/11/2009)... about the deep ocean,s temperature variability and circulation system ... The deep ocean is affected more by surface warming ... accurate predictions of factors such as sea level rise ... have also been found to result in a more ... a faster transport of large quantities of warm water, ...
(Date:12/11/2009)... moderate amount of weight by eating less and exercising ... Washington University School of Medicine in St. Louis. , ... Dec. 15, 2009, issue of the Journal of ... loss led to improvement in four key measures of ... study participants included decreased thickness of heart muscle, improved ...
Breaking Biology News(10 mins):MDC researchers identify a scaffold regulating protein disposal 2New discoveries could improve climate projections 2Moderate weight loss in obese people improves heart function 2Moderate weight loss in obese people improves heart function 3Mediterranean Diet May Be Best for Type 2 Diabetes 55765 1Mediterranean Diet May Be Best for Type 2 Diabetes 55765 2Mediterranean Diet May Be Best for Type 2 Diabetes 55765 3JFKs Health Problems More Complex Than Thought 55762 1JFKs Health Problems More Complex Than Thought 55762 2JFKs Health Problems More Complex Than Thought 55762 3Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference 55759 1
... Turn up the white noise, says a team of ... the benefits of noise. Their findings could lead to ... an assistant professor of computer science, Joseph Martin, a ... of biology, are working together to explain the biological ...
... mass index, or BMI, long considered the standard for measuring ... be as accurate as originally thought, according to new research. ... Valley State University measured the BMI of more than 400 ... ?and found that in most cases the student's BMI did ...
... but for those with arousal system disturbances in their brains, ... could sense they were really outside their own body watching ... 6 percent said they have had such an out-of-body experience. ... University of Kentucky have studied the link between out-of-body experiences, ...
Other Biology News:Noise echoes in cell communications 2BMI not accurate indicator of body fat 2Out-of-body experiences may be caused by arousal system disturbances in brain 2
Rabbit polyclonal to SpUlp2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SNNERQSLSSGSND, corresponding to amino acids 622-635 of Schizosaccharomyces pombe SpUlp2...
Lipid Phosphate Phosphohydrolase 2...
Request Info...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Biology Products: